Skip to main content
. 2016 Oct 25;28(3):519–527. doi: 10.1093/annonc/mdw560

Figure 1.

Figure 1.

(A) Unmatched Kaplan–Meier survival analysis showing a significant (P = 0.047) improvement in overall survival with neoadjuvant chemoradiotherapy plus surgery (NCRS, n = 301) compared with neoadjuvant chemotherapy plus surgery (NCS, n = 307) for esophageal adenocarcinoma. (B) Propensity-matched Kaplan–Meier survival analysis showing no significant difference (P = 0.391) in overall survival between neoadjuvant chemoradiotherapy plus surgery (NCRS, n = 221) and neoadjuvant chemotherapy plus surgery (NCS, n = 221) for esophageal adenocarcinoma.